Abstract
Objective
To determine the effects of late pregnancy and also oestrogen supplementation on the CYP2C19-mediated biotransformation of proguanil (PG) to its active antifol triazine metabolite cycloguanil (CG).
Methods
Case control study conducted on the NW border of Thailand; a single dose of PG (4 mg/kg) was administered to Karen women in late pregnancy and a single blood and urine sample taken 6 h later. Women were studied in late pregnancy (>36 weeks) and restudied 2 months after delivery. A separate cohort of Karen women newly attending a birth-control clinic were studied before and 3 weeks into their first course of oral contraceptives (OCP: levonorgestrel 0.15 mg and ethinyloestradiol 0.03 mg). Forty-five pregnant women and forty-two healthy OCP users were studied.
Results
The results were similar in both groups; pregnancy and OCP use were both associated with reduced formation of cycloguanil (CG). Impaired PG biotransformation was seen in women with the "extensive metaboliser" phenotype (urine PG/CG ratio <10). CG levels, adjusted for dose, were a median (range) 73% (−59 to 420%) higher following the pregnancy than during the pregnancy in women characterised as extensive metabolisers (P<0.001). CG levels in women characterised as extensive metabolisers were 34% (−54 to 323%) higher before than while taking the OCP (P<0.01).
Conclusion
Late pregnancy and OCP use impair biotransformation of the active antimalarial metabolite CG from the parent PG. This may be mediated by oestrogen inhibition of CYP2C19 activity. The dose of PG should be increased by 50% in these groups.
Similar content being viewed by others
References
Brabin BJ (1983) Analysis of malaria in pregnancy in Africa. Bull World Health Organ 61:1005–1016
Nosten F, ter Kuile F, Maelankiri L, Decludt B, White NJ (1991) Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 85:424–429
Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE (1987) A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol 39:261–265
Helsby NA, Ward SA, Howells RE, Breckenridge AM (1990) In-vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxlyase (P450MP) enzyme. Br J Clin Pharmacol 30:287–291
Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990) The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 30:593–598
Wangboonskul J, White NJ, Nosten F, ter Kuile F, Moody RR, Taylor RB (1993) Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. Eur J Clin Pharmacol 44:247–251
Watkins WM, Sixsmith DG, Chulay JD (1984) The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann Trop Med Parasitol 78:273–278
Jurima M, Inaba T, Kalow W (1985) Mephenytoin hydroxylase activity in human liver: inhibition by steroids. Drug Metab Dispos 13:746–749
Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68:151–159
Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173
McGready R, Stepniewska K, Edstein MD, Cho T, Gilveray G, Looareesuwan S, White NJ, Nosten F (2003) Pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharm (this issue)
Taylor RB, Moody RR, Ochekpe NA (1987) Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by HPLC. J Chromatogr 416:394–399
Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ (1987) Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 24:775–780
Edstein MD, Shanks GD, Teja-Isavadharm P, Rieckmann KH, Webster HK (1994) Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 37:67–70
Watkins WM, Mberu EK, Neville CG, Ward SA, Breckenridge AM (1990) Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan subjects. Trans R Soc Trop Med Hyg 84:492–495
Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 31:689–692
Jones K, Ward SA (2002) Biguanide-atovaquone synergy against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 46:2700–2703
Acknowledgment
We would very much like to thank the women of Maela camp who participated in this study, Julie A. Simpson for statistical advice, and Alan Brockman and his team for organising the shipping of the samples. This study was part of the Wellcome-Trust Mahidol University Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McGready, R., Stepniewska, K., Seaton, E. et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 59, 553–557 (2003). https://doi.org/10.1007/s00228-003-0651-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0651-x